Satellos Bioscience Inc MSLE 深 沪

Satellos to Present Clinical Program Updates at ICNMD 2026

Satellos Bioscience Inc. announced that new data from its SAT-3247 clinical program will be presented at the 19th International Congress on Neuromuscular Diseases in Florence, Italy, on July 8, 2026. The presentations include a poster on six-month follow-up data from Phase 1b and Phase 2 trials, as well as a Showcase Theatre presentation on SAT-3247's potential for muscle repair in Duchenne muscular dystrophy (DMD) and other degenerative muscle d...

06-25 11:00

Satellos Bioscience Announces Results of Annual Meeting of Shareholders

Satellos Bioscience Inc. announced the results of its 2026 Annual Meeting of Shareholders held on June 17, 2026, in Toronto. All nominated directors were elected, with a voting rate of 55.3%. The directors received high support, with most receiving over 99% approval, except Stephanie Brown (92.22%) and Iris Loew-Friedrich (83.76%). Shareholders also approved the reappointment of PricewaterhouseCoopers LLP as auditors. Satellos is developing SAT-3...

06-17 21:00

美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级

今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元

05-19 10:55

HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $11 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $11 price target.

05-19 01:53

Earnings Scheduled For May 15, 2026

Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...

05-15 19:11

Satellos Bioscience Q1 EPS $(0.53) Down From $(0.44) YoY

Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.53) per share. This is a 20.45 percent decrease over losses of $(0.44) per share from the same period last year.

05-15 19:09

Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience reported Q1 2026 financial results and corporate updates, including $57M raised, Nasdaq uplisting, and progress in Phase 2 BASECAMP and TRAILHEAD studies. BASECAMP, evaluating SAT-3247 in pediatric DMD patients, is enrolling at 11 active sites, with additional sites to be activated in Q2, targeting Q3 2026 enrollment completion. TRAILHEAD, assessing long-term safety and efficacy in adult DMD patients, has initiated participant...

05-15 11:00

美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价

今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元

04-29 10:28

Guggenheim Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $23

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $23.

04-28 23:26

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

04-09 11:00